Diurnal Share Discussion Threads

[best1467] 22/3/2022 07:57

Alkindi sales growth is reasonable and from the Eaton comment growing in the states but chronocort disappointing But it’s early days.
The New indication Trial placing more uncertainty and risk .
Ditest slightly delayed but not major will we see a big % drop on this news I’m not sure

[ksddw2] 22/3/2022 07:38

Where does it say it was an accounting loss? Looks like it was due to increased investment to me"Operating loss for the Period of GBP9.20m (six months ended 31 December 2020: GBP5.26m), reflecting increased investment in the product pipeline and preparations for the anticipated Efmody(R) launches across Europe"

[s34icknote] 22/3/2022 07:38

Disappointing Covid has taken its toll on getting patients in g p surgery's !!!Hopefully the pipeline will come good

[mufprat] 22/3/2022 07:27

Results out and not good I'm afraid.Further funding required to reach profitability although may be non-dilutive.Burning through cash at £10M pa.With a near £10M accounting loss.Yikes :(

[best1467] 18/3/2022 07:15

During the fourth quarter, Eton announced that it had entered into a co-promotion agreement with Tolmar Pharmaceuticals, under which Tolmar’s 62-person pediatric endocrinology sales force would promote ALKINDI SPRINKLE. Tolmar’s sales force became fully trained and started promoting ALKINDI SPRINKLE in the second half of January. Tolmar’s sales force has greatly increased the number of in-person physician visits taking place, and Eton has already seen a significant increase in new patient prescriptions for the product. The company expects the month of March to produce the highest number of monthly new patient prescriptions since the launch of ALKINDI SPRINKLE.

[daveboy19] 16/3/2022 14:06

AGL is like waiting for the in-laws to give way !

[s34icknote] 16/3/2022 12:47

As long as dddd and agl keep going up I can wait on Dnl

[daveboy19] 16/3/2022 08:13

'Another' 5 years time !!

[s34icknote] 16/3/2022 07:32

Yep Tuck them away .This could be a great pension pot in five years time !!

[best1467] 15/3/2022 07:08

Well based on the date of the post I believe an investment around the current price on the 3 stocks gives a a excellent chance of a decent return over the next 2 years with potential in Shield and 4d to happen a lot sooner

[daveboy19] 14/3/2022 08:37

What is your definition of medium term? I am coming up to my 5th anniversary here and am at a 60% loss - just curious of course !

[best1467] 14/3/2022 07:30

HarryKewell My advice would be stick with all 3 average down if you can both ways % holdings.
You only need one to be successful and you will be looking medium to longterm at a vey good return in my opinion the odds look favourable especially at these valuations

[s34icknote] 11/3/2022 17:49

Product sales should be 4.5 million !

[s34icknote] 11/3/2022 07:09

I would exclude licence feesProduct sales only Covid disappearing will help Think we have a time lag on sales because of it !Creates the buying opportunity at these levels !It's a long term play .

[daveboy19] 10/3/2022 14:35

Exciting - only another 25p to go to 4 year parity :¬)

[s34icknote] 10/3/2022 09:19

Dddd Dnl and agle my bios

[s34icknote] 10/3/2022 08:20

Just topped up here !!Tick them away long term Covid disappears sale sion

[harrykewell] 09/3/2022 17:20

I've got STX aswell as DNL and 4D.

[simon_64] 09/3/2022 15:45

Agreed this is frustrating and unexpected, but this size drop provides and opportunity, i will wait for it to reach base and add crazy price.

[daveboy19] 09/3/2022 15:08

We're about to find out ! Incredibly depressing few weeks here. Perhaps they can cheer us up on the 22nd.

[daveboy19] 09/3/2022 09:21

Yep, and on it goes.

[s34icknote] 09/3/2022 02:57

Can't believe we are in the thirties !Almost as bad as my dddd shares !

[weatherman] 08/3/2022 17:48

I was trying to work out what this means exactly " ... the Board still expects strong sales growth in total product sales in excess of 100% for the 12-month period ended 30 June 2022 compared to the prior period as the commercial roll out of Alkindi(R) and Efmody(R) continues across Europe."

Are we to assume this include licence fees last year, or net of licences?